MedTech Acquisition Corporation - MTACU STOCK NEWS

Welcome to our dedicated page for MedTech Acquisition Corporation news (Ticker: MTACU), a resource for investors and traders seeking the latest updates and insights on MedTech Acquisition Corporation stock.

MedTech Acquisition Corporation (MTACU) is a leading special purpose acquisition company focused on acquiring businesses in the healthcare technology sector. With a strong track record of identifying and investing in innovative companies, MTACU aims to bring cutting-edge medical technologies to market, improve patient outcomes, and drive growth in the healthcare industry. The company's team of industry experts and strategic partnerships enable it to evaluate potential acquisition targets rigorously and execute successful transactions that deliver value to shareholders.

11/14/2023 08:00 AM

News

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

TriSalus Life Sciences Inc. (Nasdaq: TLSI) completed a merger with MedTech Acquisition Corporation (MTAC) and started public trading on August 11th. The company reported 3Q23 revenues of $5.2 million, up 32% over the prior year, and nine-month net revenues of $12.8 million, up 39% over the prior year. Favorable Phase 1 uveal melanoma PERIO-01 data demonstrated median progression free survival (PFS) of 11.7 months, with an 81% Disease Control Rate and 1 year overall survival (OS) of 86%. Additionally, favorable Phase 1 pancreatic adenocarcinoma PERIO-03 data utilizing an innovative FDA cleared pancreatic delivery device demonstrated initial safety, feasibility, and immunologic response.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/07/2023 04:05 PM

News

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

Rhea-AI Summary

TLSI to Host Q3 Financial Results Conference Call and Webcast on November 14, 2023, at 9:00 a.m. ET

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/04/2023 02:25 PM

News

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

Rhea-AI Summary

TriSalus Life Sciences presented additional Phase 1 clinical data at the SITC 2023 Annual Meeting. The data showed that SD-101, delivered via PEDD with the TriNav Infusion System, is well tolerated and associated with immunologic effects within the liver and systemically. The median Progression-Free Survival was 11.7 months with an 81% Disease Control Rate at the optimal biologic dose of SD-101 (2 mg) in combination with nivolumab.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/03/2023 12:00 PM

News

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Rhea-AI Summary

TriSalus Life Sciences Inc. announces positive safety and feasibility data from a Phase 1 trial using its proprietary Pressure-Enabled Drug Delivery (PEDD) method to deliver an investigational TLR9 agonist, SD-101, intravascularly in pancreatic tumors. The data shows no serious adverse events related to treatment and indicates modulation of the tumor microenvironment, with decreases in myeloid derived suppressor cells (MDSC) activity and increases in T cell activation.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/25/2023 09:05 AM

News

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Rhea-AI Summary

TriSalus Life Sciences® Inc. will present new data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data includes clinical activity of SD-101 with immune checkpoint inhibition in metastatic uveal melanoma liver metastasis and initial safety and feasibility experience of pressure-enabled intrapancreatic delivery of SD-101 with checkpoint blockade for locally advanced pancreatic adenocarcinoma.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/06/2023 07:00 AM

News

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

Rhea-AI Summary

Jodi Devlin joins TriSalus as President of TriSalus Therapeutics

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/10/2023 04:05 PM

News

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

Rhea-AI Summary

TriSalus completes merger with MedTech, stock to begin trading on Nasdaq. Cash runway through mid-2024. Advances in technology and clinical trials. Positive clinical data. TriNav net sales: $8.4M (2021), $12.4M (2022), projected $19.2M (2023). TriNav LV device receives FDA clearance. SD-101 shows immune effects in liver and blood. Phase 1 data readouts planned Q4 2023, Phase 2 trial in H2 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/12/2023 07:00 AM

News

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

Rhea-AI Summary

TriSalus Life Sciences announces additional Phase 1 clinical data from PERIO-01 trial at ASCO 2023 Annual Meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/20/2023 07:00 AM

News

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

Rhea-AI Summary

TriSalus Life Sciences has announced new Phase 1 clinical data at the AACR 2023 Annual Meeting regarding its Pressure-Enabled Regional Immuno-Oncology (PERIO-01) trial for uveal melanoma with liver metastases. The trial, utilizing the investigational drug SD-101 delivered via the TriNav Infusion System, aims to enhance systemic checkpoint inhibitors' effectiveness. Of 27 enrolled patients, treatment-related adverse events were mostly non-serious, with one significant event reported. Encouragingly, ctDNA and circulating tumor cell levels decreased in several patients, indicating potential improved survival outcomes. TriSalus is preparing for a business combination with MedTech Acquisition Corporation (MTAC), projected to list under the ticker TLSI, pending necessary approvals.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/21/2023 07:00 AM

News

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

Rhea-AI Summary

TriSalus Life Sciences announced the appointment of Jim Alecxih as President of Device Technology Business. With over 30 years of experience in product development and commercialization, Alecxih will oversee the growth of the TriNav Infusion System, which has been used in over 17,000 procedures. The Company is in the process of going public through a merger with MedTech Acquisition Corporation (ticker: MTAC) expected to close in Q2 2023, pending shareholder approval. TriSalus aims to disrupt cancer treatment for liver and pancreatic tumors through innovative drug delivery technology.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is MedTech Acquisition Corporation (MTACU)?

MedTech Acquisition Corporation is a special purpose acquisition company focused on acquiring businesses in the healthcare technology sector.

What is the core business of MTACU?

MTACU's core business is to identify and invest in innovative companies in the healthcare technology sector to bring cutting-edge medical technologies to market.

What is the goal of MTACU?

MTACU aims to improve patient outcomes, drive growth in the healthcare industry, and deliver value to shareholders through strategic acquisitions.

How does MTACU evaluate potential acquisition targets?

MTACU evaluates potential acquisition targets rigorously with the help of its team of industry experts and strategic partnerships.

What sets MTACU apart from other special purpose acquisition companies?

MTACU's strong track record in identifying and investing in innovative companies and its focus on the healthcare technology sector set it apart from other SPACs.